Video

Dr. Cutler on Remaining Challenges in GVHD

Corey S. Cutler, MD, MPH, FRCPC, discusses remaining challenges in graft-versus-host disease.

Corey S. Cutler, MD, MPH, FRCPC, medical director, Adult Stem Cell Transplantation Program, director of Clinical Research, Stem Cell Transplantation, director, Stem Cell Transplantation Survivorship Program, institute physician, Dana-Farber Cancer Institute, and associate professor of medicine, Harvard Medical School, discusses remaining challenges in graft-versus-host disease (GVHD).

Early identification of patients with GVHD who are unlikely to respond well to corticosteroids remains a clinical need, says Cutler. Additionally, understanding which patients require augmented therapy up front compared with those who can receive de-escalated treatment require more study.

While biomarkers for chronic GVHD are less developed, biomarkers for acute GVHD (aGVHD) could aid in identifying these patients, explains Cutler.

The randomized phase 2 BMT CTN 1501 trial showed that single-agent sirolimus (Rapamune) is a viable option for patients with standard-risk aGVHD and is associated with reduced steroid exposure, greater immune suppression discontinuation, and improved quality of life compared with prednisone, concludes Cutler.

Related Videos
Marc Machaalani, MD
Craig Eckfeldt, MD, PhD, assistant professor, medicine, faculty, Microbiology, Immunology, and Cancer Biology PhD Graduate Program, Division of Hematology, Oncology, and Transplantation, the University of Minnesota Medical School
Alicia Morgans, MD, MPH, genitourinary medical oncologist, medical director, Survivorship Program, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School
Alfred L. Garfall, MD, MS
Razane El Hajj Chehade, MD
Mark Juckett, MD, professor, medicine, Division of Hematology, Oncology, and Transplantation, the University of Minnesota Medical School
Coral Olazagasti, MD
Barbara Jane O’Brien, MD, associate professor, Neuro-Oncology, Department of Neuro-Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Tycel Phillips, MD
Giuseppe Curigliano, MD, PhD